The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study)

Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study)
Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study)
Germline TP53 pathogenic variants are rare but associated with a high risk of cancer; they are often identified in the context of clinically diagnosed Li-Fraumeni Syndrome predisposing to a range of young onset cancers including sarcomas and breast cancer. The study aim was to conduct a detailed morphological review and immuno-phenotyping of breast cancer arising in carriers of a germline TP53 pathogenic variant. We compared breast cancers from five defined groups: (1) TP53 carriers with breast cancer (n=59), (2) early onset HER2-amplified breast cancer, no germline pathogenic variant in BRCA1/2 or TP53 (n=55), (3) BRCA1 pathogenic variant carriers (n=60); (4) BRCA2 pathogenic variant carriers (n=61) and (5) young onset breast cancer with no known germline pathogenic variant (n=98). Pathologists assessed a pre-agreed set of morphological characteristics using light microscopy. Immunohistochemistry (IHC) for HER2, ER, PR, p53, αvβ6 integrin, α-SMA and pSMAD2/3 was performed on tissue microarrays (TMA) of invasive carcinoma. We confirmed a previously reported high prevalence of HER2-amplified, ductal no special type (NST) invasive breast carcinoma amongst known TP53 germline pathogenic variant carriers 20/36 (56%). Furthermore we observed a high frequency of densely sclerotic tumour stroma in cancers from TP53 carriers (29/36, 80.6%) when compared with non-carriers, 50.9% (28/55), 34.7% (50/144), 41.4% (65/157), 43.8% (95/217) in groups 2-5 respectively. The majority of germline TP53 gene carrier breast tumours had a high intensity of integrin αvβ6, α-SMA, and pSMAD2/3 expression in the majority of cancer cells. In conclusion, aggressive HER2 positive breast cancers with densely sclerotic stroma are common in germline TP53 carriers. High levels of αvβ6 integrin, α-SMA and pSMAD2/3 expression suggest that the dense stromal phenotype may be driven by upregulated TGFβ signalling.
1-10
Packwood, Katie
511bbd2a-602e-457a-83a1-523c4cc7248e
Martland, Guy
4b811e4f-c36a-4088-8486-9d785becde90
Sommerlad, Matthew
26951faa-23a5-4266-8f38-66907bba9856
Shaw, Emily
31157e86-268e-4602-bd15-39ee9c63aaa6
Moutasim, Karwan
af7dd711-f6df-44f7-8c57-052bf15303af
Thomas, Gareth
2ff54aa9-a766-416b-91ee-cf1c5be74106
Bateman, Adrian
35f5fef8-6358-42ff-b3c1-2ff226b4dc43
Jones, Louise
68ce5626-a7bb-4856-93f3-77502a235d5e
Haywood, Linda
698b87c2-1e30-47bb-b54f-44b2cda23b82
Evans, D. Gareth
314acefb-89fb-4eb7-a0e7-0a6949c9af6c
Birch, Jillian
423d1d94-e57a-4665-baa4-3042b4fd57f6
Alsalmi, Ohud Abdullah
0606e90c-505d-4684-a700-6da173b35293
Henderson, Alex
a282c7cd-29d7-459d-8b2b-918f5fbd78d9
Poplawski, Nicola
02716850-9720-4c6b-8352-fe31ff635b74
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Packwood, Katie
511bbd2a-602e-457a-83a1-523c4cc7248e
Martland, Guy
4b811e4f-c36a-4088-8486-9d785becde90
Sommerlad, Matthew
26951faa-23a5-4266-8f38-66907bba9856
Shaw, Emily
31157e86-268e-4602-bd15-39ee9c63aaa6
Moutasim, Karwan
af7dd711-f6df-44f7-8c57-052bf15303af
Thomas, Gareth
2ff54aa9-a766-416b-91ee-cf1c5be74106
Bateman, Adrian
35f5fef8-6358-42ff-b3c1-2ff226b4dc43
Jones, Louise
68ce5626-a7bb-4856-93f3-77502a235d5e
Haywood, Linda
698b87c2-1e30-47bb-b54f-44b2cda23b82
Evans, D. Gareth
314acefb-89fb-4eb7-a0e7-0a6949c9af6c
Birch, Jillian
423d1d94-e57a-4665-baa4-3042b4fd57f6
Alsalmi, Ohud Abdullah
0606e90c-505d-4684-a700-6da173b35293
Henderson, Alex
a282c7cd-29d7-459d-8b2b-918f5fbd78d9
Poplawski, Nicola
02716850-9720-4c6b-8352-fe31ff635b74
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23

Packwood, Katie, Martland, Guy, Sommerlad, Matthew, Shaw, Emily, Moutasim, Karwan, Thomas, Gareth, Bateman, Adrian, Jones, Louise, Haywood, Linda, Evans, D. Gareth, Birch, Jillian, Alsalmi, Ohud Abdullah, Henderson, Alex, Poplawski, Nicola and Eccles, Diana (2019) Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study). The Journal of Pathology: Clinical Research, 1-10. (doi:10.1002/cjp2.133).

Record type: Article

Abstract

Germline TP53 pathogenic variants are rare but associated with a high risk of cancer; they are often identified in the context of clinically diagnosed Li-Fraumeni Syndrome predisposing to a range of young onset cancers including sarcomas and breast cancer. The study aim was to conduct a detailed morphological review and immuno-phenotyping of breast cancer arising in carriers of a germline TP53 pathogenic variant. We compared breast cancers from five defined groups: (1) TP53 carriers with breast cancer (n=59), (2) early onset HER2-amplified breast cancer, no germline pathogenic variant in BRCA1/2 or TP53 (n=55), (3) BRCA1 pathogenic variant carriers (n=60); (4) BRCA2 pathogenic variant carriers (n=61) and (5) young onset breast cancer with no known germline pathogenic variant (n=98). Pathologists assessed a pre-agreed set of morphological characteristics using light microscopy. Immunohistochemistry (IHC) for HER2, ER, PR, p53, αvβ6 integrin, α-SMA and pSMAD2/3 was performed on tissue microarrays (TMA) of invasive carcinoma. We confirmed a previously reported high prevalence of HER2-amplified, ductal no special type (NST) invasive breast carcinoma amongst known TP53 germline pathogenic variant carriers 20/36 (56%). Furthermore we observed a high frequency of densely sclerotic tumour stroma in cancers from TP53 carriers (29/36, 80.6%) when compared with non-carriers, 50.9% (28/55), 34.7% (50/144), 41.4% (65/157), 43.8% (95/217) in groups 2-5 respectively. The majority of germline TP53 gene carrier breast tumours had a high intensity of integrin αvβ6, α-SMA, and pSMAD2/3 expression in the majority of cancer cells. In conclusion, aggressive HER2 positive breast cancers with densely sclerotic stroma are common in germline TP53 carriers. High levels of αvβ6 integrin, α-SMA and pSMAD2/3 expression suggest that the dense stromal phenotype may be driven by upregulated TGFβ signalling.

Text
CJP-2018-11-0035-Herrington Edited (combined accepted) - Accepted Manuscript
Download (1MB)
Text
Packwood et al 2019 The Journal of Pathology Clinical Research - Version of Record
Available under License Creative Commons Attribution.
Download (6MB)

More information

Accepted/In Press date: 28 April 2019
e-pub ahead of print date: 30 April 2019

Identifiers

Local EPrints ID: 430634
URI: http://eprints.soton.ac.uk/id/eprint/430634
PURE UUID: 2cce186f-2395-40fd-addb-faca58d8001c
ORCID for Diana Eccles: ORCID iD orcid.org/0000-0002-9935-3169

Catalogue record

Date deposited: 07 May 2019 16:30
Last modified: 26 Nov 2021 02:34

Export record

Altmetrics

Contributors

Author: Katie Packwood
Author: Guy Martland
Author: Matthew Sommerlad
Author: Emily Shaw
Author: Karwan Moutasim
Author: Gareth Thomas
Author: Adrian Bateman
Author: Louise Jones
Author: Linda Haywood
Author: D. Gareth Evans
Author: Jillian Birch
Author: Ohud Abdullah Alsalmi
Author: Alex Henderson
Author: Nicola Poplawski
Author: Diana Eccles ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×